Skip to main content

An exceptional team with decades of experience at medical device start-ups and major corporations based in Switzerland and in California (USA)

CEO

Laurent Grandidier

Laurent is a global medtech executive with talent for turning research projects into commercially viable companies

Laurent leads the atHeart Medical team with over fifteen years of experience in medical device development and commercial leadership.

He is a veteran in innovative cardiovascular devices and brings a solid track record of successfully building and leading diverse, cross functional teams for both start-ups and Fortune 500 companies, including Xeltis, Endosense, Boston Scientific, Guidant, and Procter and Gamble.

Laurent holds several independent board positions and has received numerous professional awards including the 2018 Outstanding Executive at the Global Business Excellence Awards and the Best European CEO in Medical Devices by European CEO Magazine in 2015.

He holds a Master of Science in Computer Science from the National Institute for Applied Sciences in Lyon, France, and an MBA from INSEAD, France-Singapore.

VP Quality

Maureen Bensing

Maureen’s expertise is setting up quality systems for successful start-up organizations.

Maureen is Vice-President of Quality for atHeart Medical since April 2022. She joined the company, bringing over twenty years of distinguished quality experience in multiple, prominent cardiovascular medical device start-ups such as Twelve and Ardian.

She has previously worked both in-house and as a consultant for a number of medical device companies that have been acquired by major medical device corporations, including Medtronic.

A biomedical engineer graduate from Marquette University in Milwaukee, WI, Maureen contributed to the development of intellectual property for systems and methods related to prosthetic heart valve devices.

In her spare time, she is also a Court Appointed Special Advocate (CASA) – volunteering to enrich the lives of kids in foster care.

VP Operations

Alexander Goehring

Alex's broad range of expertise in operations and operations quality results from 30 years in the cardiac and cardiovascular medtech industry.

Alexander is Vice-President of Operations at atHeart Medical since May 2022. He has been with the company in a consulting role since it began operations in 2020.

With a drive for accomplishments and a strong compliance attitude, Alex has a remarkable experience spanning from manufacturing to clinical project management, from sales and business development to quality assurance.

Alex previously worked in-house at major corporations, such as Abbott and Guidant, and at start-up companies such as Xeltis. More recently, he also worked in the medtech industry as a consultant.

Alexander holds a biomedical engineering degree from Technical University Ulm, Germany.

VP Technology

Kuno Limacher

Kuno led the development of the reSept ASD Occluder with his expertise in engineering and cardiovascular device design.

Kuno leads the atHeart Medical product development team with twenty years of medical device engineering experience.

His efforts and leadership have been instrumental in the development of the reSept ASD Occluder since the inception of the device in 2007. Kuno is co-author on several peer-reviewed publications and co-inventor on seven published patents.

He holds a Bachelor of Science in Mechanical Engineering and a Master of Science in Industrial Management and Manufacturing, with a specialization in biocompatible materials and product management, from ETH Zurich, Switzerland.

VP R&D

Fabien Lombardi

Fabien’s successful track record in medical device development is the result of a forward-thinking mindset and strategic technical planning.

Fabien joined atHeart Medical as Vice President R&D in March 2023, leading the team driving forward the atHeart Medical R&D for next generation devices.

Fabien boasts a comprehensive 20-year background in project management, spanning across various facets from materials to the development of products. Prior to atHeart Medical, Fabien held leadership roles at startups in structural heart devices and biomaterials, including Symetis (acquired by Boston Scientific), Foldax (polymeric heart valve) and Open Stent Solutions (transcatheter mitral valve).

In addition, Fabien’s career extended to well established companies such as Vascutek/Terumo and Datascope. His professional journey has taken him to multiple European countries, Australia and the United States.

A Mechanical Engineer graduate from University of Toulon, France and from University of West Scotland in Paisley, UK, Fabien gained his master’s degree in Polymer Science at University of North London, UK. He is main inventor or co-inventor of 15 patents granted between 2016 and 2022.

VP Clinical and Regulatory Affairs

Brandi Sadowski

Brandi is a seasoned clinical and regulatory affairs leader with extensive experience building and executing successful clinical programs.

Brandi leads the atHeart Medical clinical affairs team with over twenty years of clinical affairs leadership experience.

Her expertise includes overseeing global large-scale, multicenter randomized clinical trials, including both Investigational Device Exemption (IDE) and post-market studies. In addition to creating and implementing robust clinical programs, Brandi has played a key role in numerous regulatory submissions, strategic development, diligence, and fundraising efforts.

Previously, she has held clinical leadership positions with innovative medical device companies such as EBR Systems, Cotera, Ivantis and Ardian.

Brandi holds a Bachelor of Science in Genetics from the University of Wisconsin in Madison, WI.

Chris Wiley VP for Field Operations and Therapy Development atHeart Medical
VP Field Operations and Therapy Development

Chris Wiley

Chris has 20 years of field operations’ expertise in structural heart devices for seamless clinical trial execution, deep understanding of clinicians’ needs and outstanding clinical support.

Chris is atHeart Medical’s Vice President for Field Operations and Therapy Development since July 2024, leading American and European roll-out activities of the atHeart Medical clinical trial program.

He has over 20 years of experience in clinical trials field operations and therapy development for major medical device corporations in the structural heart device industry. Prior to atHeart Medical, Chris covered leadership roles at W.L. Gore for over 17 years, including as Clinical Specialist Leader for devices for the closure of Atrial Septal Defects (ASD) and Patent Foramen Ovale (PFO), both congenital heart defects of the atrial septum.

Chris trained as a radiologic technologist in the United States Air Force where he specialized in cardiovascular interventions. He continues to bring that experience to the medical device industry for both premarket clinical device studies as well as commercial product sales and support.

In his down time, Chris enjoys traveling with his wife Erin (over 30 countries) and spending time with his son Aidan – a 3rd year medical student at the University of Maryland Medical School – and on the golf course.

Board of Directors

Chairman

Michael Larsson

Michael Larsson is a visionary entrepreneur, founder and scientist bringing forward his family legacy: improving childhood through behavioral change and science-based evidence.

Michael Larsson is Chairman of the Olle Larsson Holding (OLH), a Swiss corporate group founded by his father Olle Larsson in 2001. OLH owns a diverse portfolio of companies in medical devices, among other sectors, including atHeart Medical and the global market leader in breastfeeding pumps Medela.

As part of his role, Michael holds a number of board positions in OLH’s participated companies. In accordance with the group’s ethos, the companies invest significant focus and capital into research and development.

With his father Olle and his brother Göran, Michael was founding President of the Family Larsson-Rosenquist Foundation (FLRF). FLRF is an independent philanthropic organization and one of the first foundations in the world with a prime focus on supporting breast milk and breastfeeding. FLRF promotes research to understand the value of breast milk and breastfeeding with major research institutions globally, among other initiatives.

A trained scientist, Michael was previously involved in research studies on lactation in collaboration with the University of Western Australia that advanced the way all breastfeeding pumps work today. At FRLF, he also contributed to promote basic research to expand evidence-based knowledge and understanding of the properties of breast milk and the value of breastfeeding for a child’s life.

Board Member

Andrew Cleeland

Andrew Cleeland is a globally renown medtech leader with a strong passion for championing novel healthcare solutions.

Andrew Cleeland joined atHeart Medical’s Board of Directors when the company was just a few months old. His wealth of knowledge and business expertise have been critical input for the company’s strategic planning year on year.

Andrew has over thirty years of experience in the medical device industry, including specific expertise bringing game-changing technologies to market in organizations ranging from early-stage start-ups to large multinationals.

He is currently the CEO of Fogarty Innovation, a leading nonprofit incubator focused on visionary approaches to address unmet needs in an evolving medtech landscape.

A recognized industry leader, he is a former vice president and general manager of Medtronic’s transcatheter Mitral Valve business, following the acquisition of Twelve Inc. and Ardian Inc, which he led as CEO.

Andrew currently serves on the board of venture-funded companies Saluda Medical, Zenflow, Inc. (chairman) and MMI S.p.A. (chairman) and holds advisory positions at top-tier venture capital firms, Longitude Capital and Arboretum Ventures.

In addition, he has been involved in multiple initiatives including the UCSF-Stanford Pediatric Device Consortium, the Medical Device Innovation Consortium, and the Singapore government’s Biomedical Research Council (BMRC).

Andrew holds a Bachelor of Applied Science (biophysics) from the Swinburne Institute of Technology.

Board Member

Markus Ineichen

Markus Ineichen is deeply rooted in the values driving our founders: helping build innovative, efficient pathways to a world where every child has an optimum start in life.

For the past 18 years, Markus Ineichen has been the committed CEO of the Olle Larsson Holding (OLH). OLH is a Swiss corporate group founded by entrepreneur Olle Larsson in 2001. OLH is an evolution of Olle’s diverse portfolio of companies, following on from his successful medical and electronic business from the early 1960s in Switzerland.

A board member of atHeart Medical since its onset, Markus helps rooting the company into its holding group’s unique ethos – investing significant focus and capital into research and development, and into that of the philanthropic foundation that owns it.

OLH is the business arm of the Family Larsson-Rosenquist Foundation (FLRF) founded by Olle and his sons. FLRF is an independent philanthropic organization dedicated to childhood and one of the first foundations in the world with a prime focus on promoting and supporting breast milk and breastfeeding.

As part of his role at OLH, Markus holds a number of board member positions in companies owned by the group, in addition to atHeart Medical.

Prior to OLH, Markus was a lawyer, specialist in IP and M&A at leading Swiss and US law firms. He graduated from the University of Zurich (CH), is an alumnus of the University of Alicante in Spain and holds an MBA from the international Institute for Management Development (IMD) of Lausanne in Switzerland.

Board Member - CEO

Laurent Grandidier

Laurent is a global medtech executive with talent for turning research projects into commercially viable companies

Laurent leads the atHeart Medical team with over fifteen years of experience in medical device development and commercial leadership.

He is a veteran in innovative cardiovascular devices and brings a solid track record of successfully building and leading diverse, cross functional teams for both start-ups and Fortune 500 companies, including Xeltis, Endosense, Boston Scientific, Guidant, and Procter and Gamble.

Laurent holds several independent board positions and has received numerous professional awards including the 2018 Outstanding Executive at the Global Business Excellence Awards and the Best European CEO in Medical Devices by European CEO Magazine in 2015.

He holds a Master of Science in Computer Science from the National Institute for Applied Sciences in Lyon, France, and an MBA from INSEAD, France-Singapore.